Liposomes containing recombinant gp85 protein vaccine against ALV-J in chickens

详细信息    查看全文

• 作者：Limei Zhang^a ; Dongjie Cai^a ; Xiaona Zhao^a ; Ziqiang Cheng^a ; Huijun Guo^a ; Chunhua Qi^b ; Jianzhu Liu^a ; ^{Liujz@sdau.edu.cn" class="auth_mail} ; Ruixue Xu^a ; Peng Zhao^a ; Zhizhong Cui^a
• 关键词：ALV-J ; Recombinant gp85 protein ; Liposomes ; Viremia ; Chicken
• 刊名：Vaccine
• 出版年：1 May, 2014
• 年：2014
• 卷：32
• 期：21
• 页码：2452-2456
• 全文大小：586 K

文摘

To study the potential of liposome vaccines in the clinical prevention of ALV-J, the effect of recombinant gp85 protein of subgroup J avian leukosis virus (ALV-J) entrapped by liposomes in chickens against ALV-J infection was investigated in this paper. A recombinant plasmid (PET28a-gp85) containing the PET28a vector and gp85 gene was constructed and then expressed in Rosetta (DE3) cells with 0.5 mM IPTG to produce recombinant gp85 proteins that could be entrapped by liposomes through reverse-phase evaporation. The chickens were inoculated intramuscularly either once or twice with the liposomes or with Freund's adjuvant emulsion containing recombinant gp85 protein. Sixty chickens were raised to one week old for the first inoculation and to three weeks old for the second inoculation. Chickens raised to five weeks old were challenged with a 10^2.4 50% tissue culture infective dose (TCID₅₀) of ALV-J. Blood samples were collected from each chicken at weekly intervals for serum antibody and viremia analyses. Changes in serum antibodies showed that positive serum antibodies (S/P value >0.6) could be induced in all groups regardless of the frequency of inoculation but improved significantly in the twice-inoculated groups. As well, high levels of antibodies emerged earlier in the Freund's adjuvant groups but persisted longer in the liposome groups. Detection of viremia indicated that the liposomes provide better protection against ALV-J than Freund's adjuvant emulsion and that this protection is directly influenced by serum antibody levels. Overall, this study reveals the potential of liposome vaccines containing recombinant gp85 protein in the clinical prevention of ALV-J.